Diagnostic assay utilizing recombinant antibody technology to evaluate prostate cancer risk and aggressiveness from non-invasive urine samples. Designed for simplicity of operation and cost-effective accessibility in resource-limited settings.
Manufactured by
iPASY Technologies Kft
Veszprém, Hungary
iPASy is revolutionizing prostate cancer screening with a urine-based, non-invasive diagnostic that detects disease-specific glycan patterns of urinary PSA, offering up to six-times higher specificity than blood-based tests. Our vision is to make prostate cancer detection accurate, accessible, and patient-friendly worldwide , with upcoming launches in Europe and the U.S. in collaboration with Mayo Clinic .
© 2026 Suplivia · Home · Browse Products